A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines
Launched by VAXGEN · Aug 30, 2001
Trial Information
Current as of March 27, 2025
Completed
Keywords
ClinConnect Summary
Patients are randomized to 1 of the 2 following arms and administered 1 or 2 injections into the deltoid muscle at 0, 1, 6, and 12 months:
Arm A: Patients receive 1 of 3 doses of AIDSVAX B/B vaccine (MN rgp120/HIV-1 plus GNE8 rgp120/HIV-1) in alum adjuvant.
Arm B: Patients receive AIDSVAX B/E (MN rgp120/HIV-1 plus A244 rgp120/HIV-1) vaccine in alum adjuvant.
Patients are evaluated at 1 hr, 3 days, and 14 days after each immunization and at 18 months after the first immunization.
An interim analysis is performed after all patients receive the second dose (at 1 month).
Gender
ALL
Eligibility criteria
- Patients must:
- • Be HIV-uninfected men and women at low or intermediate risk for HIV-1 infection.
About Vaxgen
Vaxgen is a biopharmaceutical company focused on the development and commercialization of innovative vaccines to combat infectious diseases and improve public health outcomes. With a commitment to scientific excellence and patient safety, Vaxgen conducts rigorous clinical trials to evaluate the efficacy and safety of its vaccine candidates. The company leverages advanced technologies and collaborative partnerships to drive research and development, aiming to address unmet medical needs and enhance global vaccination efforts. Through its dedication to innovation and quality, Vaxgen strives to contribute significantly to the field of immunization and disease prevention.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Denver, Colorado, United States
Washington, District Of Columbia, United States
Saint Louis, Missouri, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials